SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Cranwill who wrote (176)12/6/1996 10:49:00 PM
From: I. Luttichuys   of 1762
 
Hello Roger, Your point is, as you say, a VERY powerful reason IDEC will be providing the therapy of choice for patients with NHL. It is quite common for patients to find the treatment sometimes seems, in a very real way, worse than the disease itself. Many elect to do as your friend has done. I am looking for early approval on that basis alone.
As you know (but as some others who might explore these posts may not) Chemo does not always distinguish very well between cancerous and healthy tissue because it interferes with processes such as cell division to kill cells. Cancer cells divide rapidly so in theory these cells will be proportionally more damaged by Chemo. Problem is some normal cells in the body are also rapidly dividing such as those with line the digestive tract. These are killed as well in great numbers and hence the notorious gastro-intestinal side-effects caused by Chemo.
To relieve patients of this additional and (in the event IDEC's drug is approved) unnecessary burden will strike many prescribing oncologists as a moral imperative. I myself could not imagine putting a patient through Chemo before C2B8 if C2B8 comes to market and proves as efficacious as trials show it to be thus far.
Have a Good Evening,
BENNETT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News